A Phase 2/3 interventional study of Saline and Triamcinolone with lidocaine in TMJ Pain, sponsored by Cairo University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by Cairo University · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing triamcinolone in Pain — 6 open to participants now, 6 under way, 3 of them phase 3. Triamcinolone · Pain.
Among the 21 studies testing triamcinolone in Pain, this one is the 17th largest by planned enrollment, is one of 2 that started in 2026, is the only one in phase 2/3, and was the 19th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →6 of the 21 studies testing triamcinolone in Pain are open now, in 3 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 40–75
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
Harrow Inc · Sites in United States
Ages 18+
Allama Iqbal Medical College · Sites in Pakistan
Ages 18–40 · Healthy volunteers
By country, each count listing its studies:
Triamcinolone: first FDA approval 1957 (ARISTOCORT). What it is approved for, and how studies give it, is on its page →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 7 · Phase 4 2
First in 2008; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 70 across the 21 interventional studies. Of the 14 that completed or were terminated, 12 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 21 have an industry lead sponsor. The 10 most frequent:
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
103 studies in Pain by Cairo University: 31 open now, 34 under way, 2 of them phase 3. Of 38 finished, 0 (0%) have results posted.
Among the 103 studies in Pain by Cairo University, this one is the 94th largest by planned enrollment of the 100 interventional ones that give a count, is one of 11 that started in 2026, is one of 3 in phase 2/3, reaches primary completion later than 20 of the 33 other live ones, and was the 93rd registered.
Cairo University’s Pain studies by the year they started, since 2010.
2 of the studies testing triamcinolone in Pain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07832552Phase 3Harrow IncA Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery | 2026-12 |
| NCT06004882M.D. Anderson Cancer CenterPeripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study | 2027-01-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies testing triamcinolone in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Cairo University’s 103 in Pain:
This tab as a report to print or save as PDF → With an account.
This study aims to clinically evaluate the efficacy of trigger points using active drug mix (Triamcinolone with lidocaine) on relief of myofascial pain of jaw muscle.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Drug: Saline
Drug: Triamcinolone with lidocaine
Drug: Lidocaine
Patients will take 1 ml of lidocaine 2%
Drug pages: TriamcinoloneStudies of TriamcinoloneTriamcinolone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LidocaineStudies of LidocaineLidocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Patients will take 1 ml of active drug mix (1/4 ml of Triamcinolone and 3/4 ml of lidocaine)
Patients will take 1 ml lidocaine 2%
current pain intensity
• Patients' subjective pain experience. Each patient will be asked to rate his or her current and worst pain intensity on visual analogue scale (VAS) of 0-10 with zero being no pain and ten corresponds to the worst pain that the patient ever had
Time frame: 1 week , 1 month , 3 months after treatment
maximum mouth opening
* Maximum mouth opening (MMO). Assessment of MMO will be performed by measuring the distance in mm between the incisal edges of the upper and lower central incisors using a ruler. * The postoperative demand for analgesics will be evaluated by recording the number of the analgesic's intake. * Patient satisfaction. * Pressure pain threshold (PPT). Data will be collected preoperatively, pain will be measured immediately after the treatment, as well as one week, one month, and 3 months after the end of the treatment sessions
Time frame: 1 week , 1 month , 3 months after treatment
post operative demands for analgesics
measuring unit number
Time frame: 1 week , 1 month , 3 months after treatment
patient satisfaction
measured by likert scale
Time frame: 1 week , 1 month , 3 months after treatment
pressure pain threshold (PPT)
measuresd by algometer
Time frame: 1 week , 1 month , 3 months after treatment
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Jun 2026, 3 months later.
Of 35 non-industry phase 2/3 interventional studies under Pain, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 3 months is below that.
Counting every sponsor, half of 41 studies reached it within 20 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Triamcinolone · Lidocaine